Q2
BFRI — Q2 2026 Financial Report Analysis
Biofrontera Q2 2026: revenue +32.9% to $12.0M and gross margin up to 80% on a cheaper Ameluz supply deal narrowed the loss to $0.6M, but about $1.9M of sales were early orders ahead of a lamp import ban, and cash is $4.7M with a going-concern warning.